What Olema Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 25 |
| Total trades | 0 | 44 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 592,368 |
| Disposed | 0 | 1,233,636 |
| Net activity | +0 | −641,268 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director | Jul 24 | Open-market sale · S | −12,500 | $11.71 | −$146K | 702,770 |
| Harmon Cyrus | Director | Jul 23 | Open-market sale · S | −12,500 | $11.58 | −$145K | 715,270 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 04 | Open-market sale · S | −233 | $24.69 | −$5.75K | 0 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 04 | Open-market sale · S | −24,767 | $24.25 | −$601K | 233 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 04 | Exercise / conversion · M | +25,000 | $4.37 | +$109K | 25,000 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 03 | Open-market sale · S | −15,000 | $23.01 | −$345K | 0 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 03 | Exercise / conversion · M | +15,000 | $4.37 | +$65.6K | 15,000 |
| Austin Sasha Lu | VP of Finance and Controller | Feb 02 | Grant / award · A | +11,700 | — | — | 16,188 |
| Harmon Cyrus | Director | Jan 20 | Open-market sale · S | −10,000 | $26.88 | −$269K | 727,770 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Jan 15 | Open-market sale · S | −100,000 | $28.73 | −$2.87M | 139,727 |
| Harmon Cyrus | Director | Jan 14 | Open-market sale · S | −3,489 | $29.12 | −$102K | 737,770 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 14 | Open-market sale · S | −35,003 | $28.99 | −$1.01M | 542,761 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 14 | Open-market sale · S | −14,997 | $28.60 | −$429K | 577,764 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 14 | Exercise / conversion · M | +50,000 | $4.87 | +$244K | 592,761 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 13 | Open-market sale · S | −200 | $28.49 | −$5.7K | 542,761 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 13 | Open-market sale · S | −49,800 | $27.60 | −$1.37M | 542,961 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 13 | Exercise / conversion · M | +50,000 | $4.87 | +$244K | 592,761 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Jan 13 | Open-market sale · S | −3,822 | $28.01 | −$107K | 239,727 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 12 | Open-market sale · S | −10,000 | $28.34 | −$283K | 144,846 |
| Bohen Sean | President and CEO | Dec 26 | Gift · G | −8,500 | — | — | 237,650 |
Loading...
